Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing.
Qianming BaiHong LvLonglong BaoYu YangXin ZhangHeng ChangTian XueMin RenXiaoli ZhuXiaoyan ZhouWentao YangPublished in: Breast cancer (Dove Medical Press) (2023)
Group A breast cancer, which has always been unquestionably diagnosed as HER2 amplification, was more likely to be HER2 negative and derived less benefit from anti-HER2 neoadjuvant chemotherapy. Group A breast cancer should be distinguished from classical HER2-positive breast cancers when assessing HER2 FISH, and a larger cohort of Group A patients should be included in further studies.
Keyphrases
- neoadjuvant chemotherapy
- gene expression
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- locally advanced
- machine learning
- sentinel lymph node
- dna methylation
- peritoneal dialysis
- deep learning
- prognostic factors
- breast cancer risk
- early stage
- radiation therapy
- case control
- genetic diversity